Corvex Free cash flow decreased by 130.8% to -$10.53M in Q1 2026 compared to the prior quarter. Over 2 years (FY 2021 to FY 2024), Free cash flow shows a downward trend with a 16.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$4.19M | -$4.19M | -$4.19M | -$5.82M | -$6.39M | -$6.09M | -$7.91M | -$6.98M | -$5.26M | -$4.14M | -$8.17M | -$5.67M | -$4.56M | -$10.53M |
| QoQ Change | — | +0.0% | +0.0% | -39.1% | -9.7% | +4.7% | -29.8% | +11.8% | +24.6% | +21.4% | -97.5% | +30.6% | +19.6% | -130.8% |
| YoY Change | — | — | — | — | -52.6% | -4.6% | -23.8% | — | — | +32.1% | -3.3% | +18.7% | +13.3% | — |